Ind Swift Laboratories Limited (ISLL) has announced robust financial results for the fiscal year, marking a significant milestone with the completion of its merger with Ind Swift Limited.

Financial Highlights

The company reported a standalone net profit of Rs. 256.09 crores, showcasing substantial growth. Revenue from operations stood at Rs. 549.65 crores, reflecting the company's strong market position in the pharmaceutical sector.

Merger Completion

A key development was the merger of Ind Swift Limited with ISLL. The scheme of arrangement, approved by the National Company Law Tribunal (NCLT) Chandigarh Bench on July 17, became effective on August 8. This strategic move is expected to enhance operational synergies and strengthen the company's market presence.

Share Allotment and Redemption

As part of the merger process, ISLL's Board of Directors approved the allotment of 14.20 lakh 1% Redeemable Preference Shares of Rs. 100 each to former Ind Swift Limited shareholders. The Board also approved the redemption of these preference shares in tranches, aligning with the terms of their issuance.

Equity Expansion

ISLL converted 15.32 lakh equity share warrants into equity shares, bolstering its equity base and potentially improving its capital structure.

Asset Sales and Exceptional Items

The company completed several strategic asset sales, including the divestment of plant machinery to ANG Lifesciences for Rs. 38.40 crores. Notably, exceptional items contributed Rs. 223.20 crores to profits, primarily from balances written back, significantly boosting the company's bottom line.

Financial Performance

ISLL's standalone basic earnings per share (EPS) stood at Rs. 38.08, reflecting the company's strong profitability and potential value for shareholders.

Outlook

With the successful completion of the merger and robust financial performance, Ind Swift Laboratories Limited appears well-positioned for future growth in the pharmaceutical industry. The strategic moves made are likely to have long-term positive impacts on the company's operations and market standing.

Ind Swift Laboratories Limited (ISLL) has announced a significant corporate restructuring, as the National Company Law Tribunal (NCLT) has given its approval for the merger of Ind-Swift Limited with Ind-Swift Laboratories Limited. This strategic move is set to reshape the company's structure and potentially its market position.

Key Details of the Merger

• Effective Date: The amalgamation will become effective on August 8, 2025.
• Appointed Date: March 31, 2024, has been set as the appointed date for the merger.
• Record Date: August 14, 2025, has been fixed as the record date for determining eligible shareholders of Ind-Swift Limited who will receive shares of Ind-Swift Laboratories Limited.
• Dissolution: Following the merger, Ind-Swift Limited will be dissolved without winding up.

Changes in Capital Structure

As part of the merger process, Ind-Swift Laboratories Limited will see a significant increase in its authorized share capital:

Corporate Actions and Regulatory Compliance

The company has taken several steps to ensure smooth execution of the merger and compliance with regulatory requirements:

1. The Board of Directors of ISLL met on July 31, 2025, to approve and note various aspects of the merger.
2. The company received the certified copy of the NCLT order on July 28, 2025, sanctioning the Scheme of Arrangement for the Amalgamation.
3. E-Form INC-28 will be filed by both companies on August 8, 2025, to formalize the effectiveness of the amalgamation.
4. The Memorandum of Association of Ind-Swift Laboratories Limited will be amended to reflect the changes in authorized share capital.

Implications for Shareholders

Shareholders of Ind-Swift Limited stand to benefit from this merger as they will receive shares of Ind-Swift Laboratories Limited. The specific share exchange ratio, however, was not disclosed in the available information.

Conclusion

This merger represents a significant development for both companies and their stakeholders. It is expected to lead to operational synergies and potentially strengthen the market position of the combined entity. Investors and market analysts will be keenly watching how this corporate restructuring impacts the financial performance and market valuation of Ind-Swift Laboratories Limited in the coming quarters.